- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02819986
Effectiveness of Using the Progressive Goal Attainment Program in Anxiety and Mood Disorders (PGAP)
Effectiveness and Feasibility of Using the Progressive Goal Attainment Program in Anxiety and Mood Disorders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of the present study is to determine the effectiveness of the Progressive Goal Attainment Program (PGAP) with individuals with anxiety and mood disorders. PGAP has been suggested as an effective therapy to reduce psychosocial barriers and help individuals return to life roles including readiness to return to work. PGAP has been shown to be effective with some chronic health conditions however has not been specifically studied in mental health populations.
The study consists of 10 one hour weekly therapy sessions with a clinician and follow the PGAP manual. The therapy sessions focus on reducing psychosocial risk factors that result in disability through the use of goal setting, activity planning, activation and re-engagement in activities, monitoring and challenging thoughts about return to work, and problem solving. Participants are also encouraged to participate in homework which involves daily activity planning, participating in planned activities, and tracking the activities completed. Participants will also be asked to complete short self-report questionnaires as well as a semi-structured interview about the participants anxiety, mood, impact of disability, and current functioning at the beginning of session one and within two weeks after session 10. Two short questionnaires will also be completed at each session measuring the degree to which the participants daily life impacts and is affected by anxiety or mood symptoms.
Our first hypothesis is that participants who receive PGAP will report significant reductions in functional disability as measured by self-report as well as by interview, decreases in self-reported work avoidance, increases in work readiness, and decreases in self-reported symptoms of anxiety and depression. Our second hypothesis is that mean reductions in the above-noted outcome variables will be similar in magnitude to those reported in published studies that have examined PGAP in chronic medically ill populations. Retention rates and satisfaction of the therapy will also be assessed to determine feasibility of implementing the program on a larger scale.
To examine the effectiveness of PGAP with participants with an anxiety or a mood disorder, the investigators will conduct a series of dependent sample t-tests on the outcome variables pre and post intervention. The investigators will also compare mean changes on the outcome variables to those in the published literature. The investigators will calculate retention rates with the aim of retaining more than 75% of participants, which is comparable to retention and drop out rates for psychotherapy trials with participants completing at least 8 out of 10 sessions or having returned to employment. Feasibility will also be measured by looking at satisfaction ratings. A minimal standard will be an average satisfaction rating across participants of midpoint (neutral) or above in terms of the therapy received.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3K7
- St. Joseph's Healthcare Hamilton
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants will be
- between the ages of 18 and 65 years
- have a principle diagnosis of an anxiety or mood disorder
- have had changes in their work functioning, either currently not working due to their disability or on modified/reduced work.
- be registered outpatients of the Anxiety Treatment and Research Clinic or Outpatient Mood Disorders Program, St. Joseph's Healthcare Hamilton,
- are interested in return to work or have work related goals.
Exclusion Criteria:
- current significant substance use
- acute mental health (e.g. suicidality, psychosis, mania) that would interfere with the program completion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Progressive Goal Attainment Program
10 one hour weekly therapy sessions focused on behavioural interventions
|
Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of PGAP on disability (participant perception)
Time Frame: one year
|
Level of disability will be measured using a modified version of the Pain Disability Index ( a 7 item self-report measure).
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of PGAP on symptom change
Time Frame: one year
|
Mood and anxiety symptoms will be measured using the Depression and Anxiety Stress Scales (a 21 item self-report measure).
|
one year
|
Impact of PGAP on level of interference from mood and anxiety symptoms
Time Frame: one year
|
Level of interference from mood and anxiety symptoms will be measured using the Illness Intrusiveness Rating Scale (13 item self-report measure).
|
one year
|
Impact of PGAP on fear avoidance beliefs
Time Frame: one year
|
Fear avoidance beliefs will be measured using the Fear Avoidance Beliefs Questionnaire (11 item self-report measure).
|
one year
|
PGAP retention rates
Time Frame: one year
|
Retention rates will be measured by tracking drop out rates.
|
one year
|
Satisfaction with the PGAP
Time Frame: one year
|
Satisfaction with the therapy will be assessed by using The Satisfaction with Therapy and Therapist Scale-Revised (13 item self-report measure).
|
one year
|
Impact of PGAP on disability (clinician report)
Time Frame: one year
|
Level of disability will be measured using the Multidimensional Scale of Independent Functioning (semi-structured interview).
|
one year
|
Impact of PGAP on role functioning
Time Frame: one year
|
Role functioning will be measured using the Multidimensional Scale of Independent Functioning (semi-structured interview).
|
one year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tanja Colonerus, MADS, St. Joseph's Healthcare Hamilton
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1784 (Bern University Hospital)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on Progressive Goal Attainment Program
-
MDRCBristol-Myers Squibb; VA Connecticut Healthcare System; Michael E. DeBakey VA... and other collaboratorsCompletedMental Disorders | Worries; Pain or DisabilityUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedSun Protection | Sunburn, ErythemaUnited States
-
Dartmouth-Hitchcock Medical CenterMedacta USARecruitingKnee Osteoarthritis | Knee Injuries | Knee Pain Chronic | Knee Injuries and DisordersUnited States
-
Ardea OutcomesNational Research Council, CanadaNot yet recruitingGeriatric Assessment
-
University Hospital, AkershusUniversity of OsloCompletedAttention-Deficit Hyperactivity Disorder, Unspecified TypeNorway
-
University of British ColumbiaUniversity of Melbourne; Arthritis Research Centre of CanadaCompleted
-
National University Hospital, SingaporeActive, not recruiting
-
Creighton UniversityNational Institutes of Health (NIH); National Institute of General Medical... and other collaboratorsCompletedACL TearsUnited States
-
Northeastern UniversityRecruitingOsteoarthritis, Knee | Knee Pain ChronicUnited States
-
Federal University of São PauloCompletedFibromyalgia